Weekly paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC)

7336 Background: Weekly schedule of P administration (WP) has already been extensively used especially for breast cancer due to its mild toxicity profile with the better feasibility than conventional tri weekly schedule of P administration.(TP). The present study was conducted to evalutate that WP may produce the same efficacy or toxicity profile for NSCLC as well as breast cancer. Patients and Methods: A single arm phase II study of WP was conducted to evaluate efficacy and safety in patients with advanced NSCLC. The present results were historically compared with the previous data of TP in the same trial group in Japan. Eligibility included < 75 years old, histologically or cytologically proven NSCLC, stage IIIB or IV, chemotherapy naive, and performance status (PS) of 0 to 2. Patients received Paclitaxel 100mg/sqm per week for 6 consecutive weeks followed by 1 week treatment off (1 course includes 7 weeks). On the other hand, patients in the historical TP group received P 210mg/sqm in every 3-weeks and...